C2orf68

Across TCGA pan-cancer cohorts, C2orf68 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C2orf68 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C2orf68 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C2orf68 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where C2orf68 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.876	0.557	.002	26	view →
LUAD	DFS	Quartile	All	0.419	0.868	.016	2	view →
GBM	DFS	Median	All	0.878	0.620	.025	2	view →
CCRCC	OS	Median	All	1.000	0.884	.033	1	view →
HNSC	OS	Median	IV	0.940	0.631	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C2orf68–PDAC (DFS)

Open the PDAC breakdown →